You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Harvard Business School
Express Scripts
Boehringer Ingelheim
Mallinckrodt
AstraZeneca

Last Updated: February 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ECULIZUMAB

See Plans and Pricing

« Back to Dashboard

Biosimilar Clinical Trials for eculizumab

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT04058158 A Study to Compare SB12 (Proposed Eculizumab Biosimilar) to Soliris in Subjects With Paroxysmal Nocturnal Haemoglobinuria Recruiting Samsung Bioepis Co., Ltd. Phase 3 2019-08-01 This is a randomised Phase III, double-blind, multicentre, cross-over study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and SolirisĀ® in subjects with PNH.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for eculizumab

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00098280 Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 2004-12-01 This study will examine the safety and effectiveness of the experimental drug eculizumab in treating patients with paroxysmal nocturnal hemoglobinuria (PNH), a rare disorder of red blood cells that leads to premature destruction of the cells and resulting anemia. Patients may be at high risk of blood clots and may develop bone marrow failure or aplastic anemia, with low white blood cell and platelet counts. Eculizumab is a monoclonal antibody that may help improve the survival of red blood cells. Patients 18 years of age and older with PNH who require blood transfusions for anemia and have received at least four transfusions in the 12 months preceding evaluation for this study may be eligible to enroll. Candidates are screened with a medical history, physical examination, and check of vital signs. Participants have an electrocardiogram (EKG) and blood and urine tests, and are vaccinated against Neisseria meningitides, a common bacteria that can cause a disabling or fatal type of meningitis. They then enter an observation phase of the study, with monthly visits during which they complete a questionnaire; update their health status, transfusion record, and medication use; have their vital signs checked and PNH symptoms evaluated; have blood and urine tests; and receive a transfusion, if necessary. These visits continue for up to 3 months until patients receive a "qualifying" transfusion; that is, a transfusion given as a consequence of a certain hemoglobin level with symptoms or a different level without symptoms. Patients are then randomly assigned to receive either eculizumab or a placebo (salt solution with no active ingredient). Both study medications are given intravenously (through a vein) over 30 minutes once a week for five doses and then once every 2 weeks for another 11 doses. At each treatment visit (study weeks 0-24), patients update their health status, transfusion records, and medication use; have their vital signs checked; and provide a blood sample. At various visits, they also complete a questionnaire, provide a urine sample and have an EKG. At the last treatment visit (week 26 or the final visit for patients who end their participation before visit 18) patients have a complete physical examination in addition to the procedures listed above.
NCT00122304 Study of Safety in Hemolytic Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Treated With Eculizumab Completed Alexion Pharmaceuticals Phase 3 2004-12-01 The primary objective is to evaluate the safety of eculizumab in patients with transfusion-dependent hemolytic PNH
NCT00122317 Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Completed Alexion Pharmaceuticals Phase 3 2005-05-01 The purpose of this study is to evaluate the long-term safety of eculizumab in patients with transfusion dependent hemolytic PNH.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for eculizumab

Condition Name

Condition Name for eculizumab
Intervention Trials
Atypical Hemolytic Uremic Syndrome 8
Paroxysmal Nocturnal Hemoglobinuria 6
Hemoglobinuria, Paroxysmal 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for eculizumab
Intervention Trials
Hemoglobinuria, Paroxysmal 19
Hemoglobinuria 18
Syndrome 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for eculizumab

Trials by Country

Trials by Country for eculizumab
Location Trials
United States 197
Japan 28
Australia 27
Italy 23
Germany 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for eculizumab
Location Trials
New York 18
Maryland 14
California 13
Ohio 11
North Carolina 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for eculizumab

Clinical Trial Phase

Clinical Trial Phase for eculizumab
Clinical Trial Phase Trials
Phase 4 3
Phase 3 12
Phase 2/Phase 3 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for eculizumab
Clinical Trial Phase Trials
Completed 20
Recruiting 15
Not yet recruiting 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for eculizumab

Sponsor Name

Sponsor Name for eculizumab
Sponsor Trials
Alexion Pharmaceuticals 39
National Heart, Lung, and Blood Institute (NHLBI) 3
Mario Negri Institute for Pharmacological Research 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for eculizumab
Sponsor Trials
Industry 53
Other 39
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Medtronic
Harvard Business School
Baxter
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.